Welcome to our dedicated page for ACCURAY SEC filings (Ticker: ARAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ACCURAY's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ACCURAY's regulatory disclosures and financial reporting.
Accuray Incorporated reported weaker results for the quarter ended December 31, 2025. Total net revenue fell to $102.2 million from $116.2 million a year earlier, as product sales declined notably, partly offset by higher service revenue.
The company swung to a net loss of $13.8 million for the quarter, versus net income of $2.5 million in the prior-year period, as gross profit dropped and it recorded $6.1 million of restructuring charges. For the first six months, revenue was $196.2 million with a net loss of $35.4 million.
Accuray ended the period with $41.3 million in cash and cash equivalents and total assets of $448.0 million. Debt remains substantial, with $149.2 million outstanding under a high-cost term loan and $18.0 million of 3.75% convertible notes. Management cites inflation, supply chain pressures, and weaker radiotherapy capital spending as ongoing headwinds, but believes current cash, facilities, and expected cash flows will fund operations for at least the next 12 months, while noting uncertainty around future compliance with financial covenants.
Accuray Incorporated filed an amended quarterly report to restate its remaining performance obligations (RPO) disclosure and acknowledge internal control weaknesses. After re-evaluating its ASC 606 methodology, the company reduced total RPO as of September 30, 2025 to $59.3 million, down sharply from $866.0 million previously disclosed, mainly by excluding open system orders, upgrade orders, and customer credits that lacked substantive termination penalties.
The restatement does not change the previously reported balance sheet, income statement, equity, or cash flow figures, but prior RPO disclosure for the quarter can no longer be relied upon. Management and the audit committee concluded disclosure controls and procedures were not effective as of September 30, 2025 due to material weaknesses in review of footnote schedules and analysis of information for complete and accurate GAAP disclosures, and outlined remediation steps to strengthen these controls. For the quarter, Accuray reported net revenue of $93.9 million and a net loss of $21.7 million, with higher interest expense tied to its new term loan facilities.
Accuray Incorporated filed an amended Annual Report to restate its disclosure of remaining performance obligations (RPO) after discovering significant errors in how open system orders, upgrades and customer credits were classified under ASC 606. RPO balances were reduced to $60.9 million from $818.2 million as of June 30, 2025, with similar large reductions for prior quarters. The company states these errors did not affect its balance sheets, income statements or cash flow statements. Management and the audit committee concluded prior financial statements for the affected periods should no longer be relied upon, and internal control over financial reporting and disclosure controls were not effective due to material weaknesses in review of footnote schedules and ASC 606 judgments.
Accuray Incorporated has filed a notice that it will not submit its Form 10‑Q for the quarter ended December 31, 2025 on time. The delay stems from recently discovered errors in the disclosure of remaining performance obligations in Note 2 of its previously filed fiscal 2025 Form 10‑K and related 10‑Qs.
The company states these errors are expected to have no impact on its balance sheets, income statements, cash flow statements, or financial metrics outside that note. Accuray is working with its auditors on amended Form 10‑K/A and 10‑Q/A filings and currently expects to file the delayed Form 10‑Q within the five‑day extension allowed under Rule 12b‑25.
Accuray Incorporated determined that investors should no longer rely on certain previously issued financial statements because of errors in how it disclosed remaining performance obligations (RPO) under ASC 606.
The issue is limited to an RPO footnote in Note 2, Revenue, and is not expected to affect the company’s balance sheets, income statements, or cash flow statements, nor the underlying value of open system and upgrade sales orders. The problem arose from a long‑standing methodology that incorrectly treated certain open orders as RPO when customer deposits did not represent substantive termination penalties.
Accuray’s audit committee concluded that the audited financial statements for the year ended June 30, 2025, related quarterly financials for fiscal 2025, and the quarter ended September 30, 2025, along with the related audit report, should not be relied upon. The company identified material weaknesses in internal control over financial reporting and disclosure controls and procedures, will file amended 10‑K/A and 10‑Q/A reports to correct the errors, and has begun remediation efforts. Management has discussed the matter with Grant Thornton LLP, its independent auditor, and currently expects to file the delayed quarterly report within the five‑day extension allowed under Rule 12b‑25.
Accuray Incorporated disclosed that on February 2, 2026 it received a notice from Nasdaq that its common stock no longer meets the Nasdaq Bid Price Rule, which requires a minimum $1.00 per share closing bid for 30 consecutive business days. The stock remains listed and trading under “ARAY” for now.
Accuray has a 180-day compliance period, until August 3, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days, subject to possible Nasdaq extension. If it fails, the company may seek a second 180-day period by transferring to the Nasdaq Capital Market and potentially effecting a reverse stock split, but there is no assurance it will qualify or avoid delisting. The company is evaluating options and states it intends to timely regain compliance.
Accuray Incorporated furnished an 8-K to share that it has released its financial results for the fiscal 2026 second quarter ended December 31, 2025. The results are contained in a press release dated February 4, 2026, which is attached as Exhibit 99.1.
The company also prepared an investor presentation attached as Exhibit 99.2, which its spokespersons plan to use with analysts and investors on or after February 4, 2026, and to post on its investor relations website. Both the press release and presentation are furnished, not filed, limiting their treatment under certain Exchange Act liability provisions.
The Vanguard Group has filed a Schedule 13G reporting a 5.13% beneficial ownership stake in Accuray Inc. common stock. Vanguard reports beneficial ownership of 5,818,576 shares as of 12/31/2025, with shared voting power over 803,553 shares and shared dispositive power over all 5,818,576 shares.
The firm states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Accuray. Vanguard notes an internal realignment effective 01/12/2026 and anticipates that certain subsidiaries will report beneficial ownership separately going forward.
Accuray Incorporated reported that Sandeep Chalke has notified the company of his intent to resign from his role as Senior Vice President and Chief Commercial Officer. His resignation will be effective on March 31, 2026. The company states that his decision is not due to any disagreement with Accuray, its Board of Directors, or any matter related to its operations, policies, or practices. This is a leadership change disclosure and does not include financial results or transaction details.
Accuray director Byron C. Scott reported equity award activity tied to his retirement from the Board of Directors on December 31, 2025. On that date, 9,433 restricted stock units were converted into an equal number of common shares at an exercise price of $0, with vesting accelerated due to his retirement. Also on December 31, 2025, 3,774 common shares were withheld at $0.8246 per share to cover a cash settlement election under the grant agreement, reducing the reported common stock position to 158,953 shares held directly. Following these transactions, he also held 47,170 restricted stock units directly, including an award that vests 100% on November 13, 2026.